Merkoša sitáhtat
APA-čujuhus (7. p.)
Shimoi, T., Sunami, K., Tahara, M., Nishiwaki, S., Tanaka, S., Baba, E., . . . Yamamoto, N. (2024). Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): A multicentre, open-label, and single-arm phase II trialResearch in context. Elsevier.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Chicago-čujuhus (17. p.)
Shimoi, Tatsunori, et al. Dabrafenib and Trametinib Administration in Patients with BRAF V600E/R or Non-V600 BRAF Mutated Advanced Solid Tumours (BELIEVE, NCCH1901): A Multicentre, Open-label, and Single-arm Phase II TrialResearch in Context. Elsevier, 2024.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
MLA-čujuhus (9. p.)
Shimoi, Tatsunori, et al. Dabrafenib and Trametinib Administration in Patients with BRAF V600E/R or Non-V600 BRAF Mutated Advanced Solid Tumours (BELIEVE, NCCH1901): A Multicentre, Open-label, and Single-arm Phase II TrialResearch in Context. Elsevier, 2024.
Kopierejuvvon čuohpusbeavdái
Kopieren čuohpusbeavdái ii lihkostuvvan
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.